Conference Coverage: ASCO GU 2025 Highlights

Expert perspectives and strategic insights on the latest therapeutic developments in GU cancer treatment from the 2025 ASCO GU Cancers Symposium, and implications on individualized clinical decision-making

February 19, 2025
Purchase Report
Daniel Petrylak, MD, Yale, Aptitude Health

FACULTY CHAIR

Daniel Petrylak, MD

Yale Cancer Center, New Haven, CT, USA

Faculty Members

Oliver Sartor, MD
Mayo Clinic, Rochester, MN, USA

Scott Tagawa, MD, FASCO, FACP
Weill Cornell Medicine, New York, NY, USA

Susan Slovin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Robert Dreicer, MD, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, USA

Joaquim Bellmunt, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA

Karim Fizazi, MD
Institut Gustave Roussy, Villejuif, France

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Prostate Cancer Part 1 – Localized Prostate Cancer
  • Prostate Cancer Part 2 – Metastatic Prostate Cancer
  • Renal cell carcinoma
  • Bladder Cancer Part 1 – Nonmuscle Invasive and Muscle Invasive
  • Bladder Cancer Part 2 – Advanced and Metastatic Disease

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.